News Channels

20 May 2022 Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
20 May 2022 Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study
20 May 2022 Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
20 May 2022 Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
20 May 2022 Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
19 May 2022 Almirall and Evotec enter into a multi-target alliance in Medical Dermatology
19 May 2022 US FDA accepts Cytovation's IND application for Phase II combination studies of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
19 May 2022 ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference
19 May 2022 Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
19 May 2022 EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 Vaccine Candidate
18 May 2022 Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
18 May 2022 Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression
18 May 2022 XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
18 May 2022 Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
18 May 2022 Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
18 May 2022 AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia
18 May 2022 Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes
18 May 2022 Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia
18 May 2022 Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
18 May 2022 Successful Completion of Phase I Study for Lead Asset EP395

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up